The short answer
“70-fold absorption,” “x185,” “ultimate bioavailability”: curcumin labels battle it out with multipliers. These figures come from small pharmacokinetic studies that cannot be compared with one another, and almost never from a trial measuring whether you actually hurt less.
Standard curcumin is poorly absorbed and rapidly metabolized. Improving exposure therefore makes sense, but that does not make “99% of supplements useless” or automatically crown a winner among piperine, phytosomes, liposomes or nanoparticles.
A formulation must be assessed on two separate levels:
- pharmacokinetics: the amount of curcumin and metabolites measured in the blood
- clinical efficacy: an actual improvement in pain, function or another relevant outcome
A product can multiply the area under the curve without multiplying the benefit. “x20,” “x29” and “x70” comparisons are not interchangeable, because studies do not always measure the same molecules, dose or duration.
For a specific goal such as knee osteoarthritis, choose a formulation tested in a relevant clinical trial rather than the one boasting the biggest absorption multiplier.
Why so little curcumin circulates
Curcumin is a fat-soluble polyphenol found in turmeric. After ingestion, several obstacles reduce the amount of free curcumin found in the blood:
- low solubility in the watery contents of the intestine
- incomplete absorption
- rapid metabolism in the intestine and liver, particularly through conjugation
- relatively rapid elimination of the free form
It is an overstatement to say the molecule is “neutralized” as soon as it undergoes glucuronidation. Some metabolites can circulate or be deconjugated in tissues. Some effects may also occur through the intestine. Free curcumin concentration is therefore not the only explanation for a clinical result.
Experiments on NF-κB, Nrf2 or BDNF generate biological hypotheses. They do not demonstrate that a capsule protects the brain, creates neurons or slows aging in humans.
Piperine: a real result, often misinterpreted
The landmark 1998 study gave healthy volunteers 2 g of curcumin alone, then 2 g of curcumin with 20 mg of piperine. Adding piperine increased reported bioavailability by 2,000%, or approximately twentyfold.
This figure has three major limitations:
- the human sample was very small
- the 2 g dose is not representative of every supplement on the market
- the study measured short-term exposure, not an improvement in pain or health
Piperine inhibits glucuronidation processes and can influence enzymes and transporters involved in drug disposition. The property that increases curcumin exposure can therefore also change exposure to a medication. If you take an anticoagulant, antiplatelet, diabetes medication, antiepileptic, immunosuppressant or a drug with a narrow therapeutic index, have a pharmacist check the product.
Piperine is neither essential nor superior by default. It is a pharmacokinetic strategy with a benefit and a potential downside.
Phytosomes, liposomes and dispersions
Phytosome
In a phytosome, curcuminoids are complexed with phospholipids, often phosphatidylcholine. The aim is to improve their dispersion and intestinal absorption. Some formulations have been evaluated in osteoarthritis, which tells you more than a simple absorption multiplier.
Liposome
A liposome is a vesicle with a lipid bilayer. Its stability depends on composition, size, manufacturing and storage. The word “liposomal” on a label proves neither the final structure after storage nor better clinical efficacy.
Micelles, colloids and solid dispersions
Other products use micelles, essential oils, polysaccharides or particle-size reduction. The term “nanoparticle” covers very different technologies. An animal study on a PLGA nanoparticle does not validate a commercial powder called “nano-curcumin.”
Bioavailability multipliers can only be compared if several parameters are identical:
- curcuminoid dose
- reference comparator
- whether free curcumin or total curcuminoids are measured
- sampling and follow-up duration
- area under the curve and maximum concentration
- human, animal or cell study
Without this information, “x70” is mostly a marketing figure.
Clinical efficacy is about more than absorption
Osteoarthritis is the area with the most human evidence. A 2021 systematic review and meta-analysis pooled fifteen randomized trials and 1,621 participants. Extracts of Curcuma longa and curcumin improved pain and function on average compared with placebo.
This conclusion needs to stay in perspective. Formulations, doses, durations, comparators and risks of bias varied. Indirectly comparing curcumin with nonsteroidal anti-inflammatory drugs in a few trials does not prove general equivalence or justify stopping treatment.
For other popular claims, the evidence is weaker or less applicable. Better absorption does not support claims that curcumin:
- prevents Alzheimer’s disease
- treats depression
- protects against cancer
- increases BDNF in a clinically useful way
- slows biological aging
- replaces a prescribed anti-inflammatory drug
A formulation can work for osteoarthritis pain without becoming a universal tool against “inflammation.”
How to choose for a joint-related goal
Start by checking the diagnosis. A hot, swollen joint, unusual nighttime pain, an injury, a fever or a locked joint requires medical assessment.
If you are considering supplementation for diagnosed osteoarthritis, assess the product using this checklist:
- the exact formulation has been used in at least one controlled human trial
- the daily curcuminoid dose matches that trial
- sufficient duration, often eight to twelve weeks
- no blend that makes it impossible to attribute the result
- independent batch testing and traceability
- cost calculated for the entire trial period
Do not transfer the dose of one formulation to another based solely on the absorption multiplier. A capsule containing 500 mg of turmeric powder, an extract containing 95% curcuminoids and a 500 mg phospholipid complex do not provide the same intervention.
A cautious trial protocol
The literature does not support a universal dose valid for every technology. Use the dose of the formulation that produced the effect in the corresponding trial.
To reduce errors in interpretation, proceed as follows:
- at baseline, rate pain out of 10 and assess a specific functional task, such as climbing stairs
- keep medical treatment, activity and other supplements stable
- take the product according to the studied protocol, generally with a meal if the instructions specify this
- record pain, function and adverse effects each week
- stop if you develop symptoms of liver problems, unusual bleeding or clear worsening
- reassess with a healthcare professional after eight to twelve weeks
If the improvement is not noticeable and functional, a theoretical biomarker change does not justify continuing.
Safety: the overlooked issue with highly absorbed formulations
Curcumin and turmeric are often well tolerated in the short term, but can cause nausea, reflux, diarrhea or abdominal pain. They may be unsuitable if you have gallstones, bile duct obstruction or a risk of bleeding.
The US Drug-Induced Liver Injury Network reported ten cases of liver injury attributed to turmeric. Five people were hospitalized and one died of acute liver failure. Three of the seven products analyzed also contained piperine. This case series cannot establish a frequency, but it shows that a natural product can also cause serious harm.
Stop the supplement and seek prompt medical advice if you notice any of the following signs:
- yellow skin or eyes
- dark urine or very pale stools
- widespread itching
- severe fatigue, persistent nausea or pain under the right ribs
- unusual bleeding or bruising
Avoid self-supplementation during pregnancy or breastfeeding, before surgery, if you have liver or biliary disease, or if you take regular medication without a pharmacist’s approval.
The Verdict
Standard curcumin has low systemic exposure, but ranking technologies by their multipliers is a poor way to shop. Piperine genuinely increases exposure in a small study, while adding potential interactions. Phytosomes, liposomes and dispersions can improve absorption, but only a clinical trial on the exact formulation answers the question that matters.
For diagnosed osteoarthritis, a studied formulation may be worth an eight-to-twelve-week trial. The comparison boswellia or ibuprofen covers the other plant often suggested for this indication, and the list of anti-inflammatory foods puts turmeric back on your plate. For neuroprotection, cancer or longevity, bioavailability does not fill the gap left by a lack of clinical evidence. The best product is not the one promising x70, but the one whose dose, results and safety are traceable.
